Objective: We aimed to evaluate whether triglyceride and glucose (TyG) indices are useful in identifying insulin sensitivity/resistance in women with polycystic ovary syndrome (PCOS). Methods: One hundred and seventy-two Korean women aged 18-35 years who were diagnosed with PCOS were included in this study. Fasting-state insulin sensitivity assessment indices (ISAIs) derived from a combination of fasting insulin and glucose levels were calculated for all study participants, and abnormal insulin sensitivity was defined as any of the evaluated ISAIs being out of the established normal range. Correlation analysis was conducted to assess the relationship between the TyG index and other clinical and biochemical parameters. Receiver operating characteristic (ROC) curve analysis was used to determine the optimal cutoff value of the TyG index for identifying abnormal insulin sensitivity, and unpaired t-tests were used to compare biochemical parameters between individuals with a TyG index below the cutoff and individuals with a TyG index above the cutoff value. Results: All clinical parameters, except age and other insulin resistance-related biochemical parameters, were significantly related to the TyG index. The ROC curve analysis revealed an optimal TyG cutoff value of 8.126 (sensitivity, 0.807; specificity, 0.683) for identifying abnormal insulin sensitivity. In the comparative analysis, all ISAIs and parameters derived from the lipid profiles differed significantly between the TyG groups. Conclusion The TyG index is a feasible surrogate marker for predicting insulin sensitivity/resistance in women with PCOS.

PURPOSE: To evaluate the therapeutic effect of human embryonic stem cell (hESC)-derived multipotent mesenchymal stem cells (M-MSCs) on ketamine-induced cystitis (KC) in rats. METHODS: To induce KC, 10-week-old female rats were injected with 25-mg/kg ketamine hydrochloride twice weekly for 12 weeks. In the sham group, phosphate buffered saline (PBS) was injected instead of ketamine. One week after the final injection of ketamine, the indicated doses (0.25, 0.5, and 1×106 cells) of M-MSCs (KC+M-MSC group) or PBS vehicle (KC group) were directly injected into the bladder wall. One week after M-MSC injection, the therapeutic outcomes were evaluated via cystometry, histological analyses, and measurement of gene expression. Next, we compared the efficacy of M-MSCs at a low dose (1×105 cells) to that of an identical dose of adult bone marrow (BM)-derived MSCs. RESULTS: Rats in the KC group exhibited increased voiding frequency and reduced bladder capacity compared to rats of the sham group. However, these parameters recovered after transplantation of M-MSCs at all doses tested. KC bladders exhibited markedly increased mast cell infiltration, apoptosis, and tissue fibrosis. Administration of M-MSCs significantly reversed these characteristic histological alterations. Gene expression analyses indicated that several genes associated with tissue fibrosis were markedly upregulated in KC bladders. However the expression of these genes was significantly suppressed by the administration of M-MSCs. Importantly, M-MSCs ameliorated bladder deterioration in KC rats after injection of a low dose (1×105) of cells, at which point BM-derived MSCs did not substantially improve bladder function. CONCLUSIONS: This study demonstrates for the first time the therapeutic efficacy of hESC-derived M-MSCs on KC in rats. M-MSCs restored bladder function more effectively than did BM-derived MSCs, protecting against abnormal changes including mast cell infiltration, apoptosis and fibrotic damage.
Adult ; Animals ; Apoptosis ; Bone Marrow ; Cystitis ; Female ; Fibrosis ; Gene Expression ; Human Embryonic Stem Cells ; Humans ; Ketamine ; Mast Cells ; Mesenchymal Stromal Cells ; Multipotent Stem Cells ; Pelvic Pain ; Rats ; Urinary Bladder